Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs MorphoSys AG

Teva vs. MorphoSys: A Decade of Diverging SG&A Strategies

__timestampMorphoSys AGTeva Pharmaceutical Industries Limited
Wednesday, January 1, 201496890005078000000
Thursday, January 1, 2015104310004717000000
Friday, January 1, 201696180005096000000
Sunday, January 1, 2017123480004986000000
Monday, January 1, 2018283102414214000000
Tuesday, January 1, 2019593361473806000000
Wednesday, January 1, 20201591459413671000000
Friday, January 1, 20211998000003528000000
Saturday, January 1, 2022902250003445000000
Sunday, January 1, 2023925380003498000000
Monday, January 1, 20243702000000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceutical Giants: Teva vs. MorphoSys

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. Over the past decade, Teva Pharmaceutical Industries Limited and MorphoSys AG have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Teva, a global leader, has seen its SG&A costs decrease by approximately 31% from 2014 to 2023, reflecting strategic cost management amidst market challenges. In contrast, MorphoSys AG, a biotech innovator, experienced a staggering 857% increase in SG&A expenses during the same period, highlighting its aggressive expansion and investment in innovation. This divergence underscores the distinct paths these companies are taking: Teva's focus on efficiency and MorphoSys's commitment to growth. As the industry continues to face regulatory and competitive pressures, these financial strategies will play a pivotal role in shaping their futures.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025